| 
			
			 For his mother, Esperanza Paz, the ordeal is compounded by fears of 
			another round of shortages in the supply of the life-saving 
			vincristine drug needed to treat the soft-tissue cancer in her son's 
			forearm. 
 "He can relapse. The cancer can come back," said Paz, after a vital 
			round of chemotherapy was delayed by a week in mid-January due to 
			vincristine shortages in his Mexico City hospital.
 
 "The concern is that Hermes is now in the final stage of his 
			treatment. We only need two cycles of chemotherapy to finish," added 
			Paz, a crafts-maker who lives with her three small children in a 
			modest home in the capital.
 
 Hermes, who has undergone three surgeries since October 2018, is one 
			of dozens of children whose cancer treatment has been imperilled by 
			shortages following a procurement shake-up by President Andres 
			Manuel Lopez Obrador's government, which centralized drug purchases 
			to reduce corruption and overpricing.
 
			
			 
			
 Lawyer Andrea Rocha represents parents of more than 60 children, 
			mostly cancer patients, who have been unable to find the correct 
			medicines in Mexico in recent months. She has filed lawsuits aimed 
			at compelling the government to give the children medicine.
 
 The festering issue has morphed into a major headache for Lopez 
			Obrador, popular for his promises to improve the lot of Mexico's 
			most vulnerable. Images of sick children and distraught parents 
			criticizing the government from crowded hospital wards have led to 
			tough questions aimed at the president in news conferences.
 
 Lopez Obrador has said in recent weeks that Mexico now has enough 
			medicines. He said scarcity in recent months was linked to Mexican 
			pharmaceutical distributors who were resisting the procurement 
			changes, along with hospital officials who he said hoarded medicines 
			and supply issues from drug companies in China and India.
 
 The president's office and the health ministry did not respond to a 
			request for comment.
 
 Sporadic shortages of medicines predate Lopez Obrador, but the rise 
			in protests from parents is a sign the problem has worsened. 
			[nL4N2332WL] Mexico's National Human Rights Commission, an 
			independent government body, said it had received more than 500 
			complaints about shortages since November.
 
 
			
			 
			"We didn't have a first-rate health system before but since the 
			change of administration, the problem of shortages has grown 
			immensely," said Rocha. "There has never been such a big crisis."
 
			
            [to top of second column] | 
            
			 
			For a while, some parents were able to deal with the problem by 
			forking out extra cash to buy prescription medicine in private 
			pharmacies. But they say some drugs are now unavailable even 
			privately.
 On Jan. 1, the government scrapped the Popular Insurance healthcare 
			system, which charged fees and had a membership system. Instead, it 
			launched a universal healthcare system that is free at point of use, 
			the Health Institute for Wellbeing, or Insabi.
 
 "The president tells us that there will be a total supply from 
			December 1. But cancer does not wait," said Paz, referring to Lopez 
			Obrador's recent comments that Insabi would provide access to free 
			medicine and a health system comparable to Denmark's before the end 
			of the year.
 
 Denmark allocates more than 10% of its GDP to health, while Mexico 
			contributes 5.9%.
 
 ORGAN FAILURE
 
 Childhood cancer is the second-highest cause of death among children 
			in Mexico, according to official figures. Each year, an average of 
			2,300 children die from 7,500 new cases.
 
 While official data is not available, parents say two young boys 
			died because of the lack of medicine in recent months.
 
 The shortages are also impacting non-cancer patients, including 
			children who underwent organ transplants.
 
 This is particularly dangerous for children such as 7 year-old 
			Diana, who has had 19 operations and had to wait four years for a 
			kidney transplant.
 
			 
			Her mother, Monica Marquez, a 41-year-old handicraft seller, said 
			she had to pay out of pocket and rely on donations to buy Tacrolimus 
			and Mycophenolic acid, two vital immunosuppressive drugs for her 
			daughter.
 But shortages have caused the price of Tacrolimus to shoot up from 
			2,500 pesos ($135) to 14,000 pesos ($755) for a two-week dose, 
			making it unaffordable for low-income families.
 
 Fearing her daughter will relapse and "go back to the way she was 
			before," Marquez's frustration with the government grows.
 
 "I feel that they are underplaying it," she said. "They are trying 
			to cover the sun with a finger when clearly there is a very big 
			problem."
 
 (Writing by Drazen Jorgic; Editing by Frank Jack Daniel and Dan 
			Grebler)
 
			[© 2020 Thomson Reuters. All rights 
				reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |